PROKIDNEY CORP (PROK)
KYG7S53R1049 - Common Stock
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ProKidney (NASDAQ:PROK) just reported results for the first quarter of 2024.Pro...
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
PROK stock results show that ProKidney beat analyst estimates for earnings per share the first quarter of 2024.
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on...
Commit To Buy ProKidney Corp At $2.50, Earn 50.1% Annualized Using Options
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of...
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company
ProKidney to Participate in Jefferies Biotech on the Bay Summit
ProKidney to Participate in Jefferies Biotech on the Bay Summit
WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics...
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney...
7 Penny Stocks With Low Floats and High Short Interest
Is the 'smart money' on the money shorting these low-float penny stocks, or is there the opportunity for a short squeeze? Let's find out.
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
WINSTON-SALEM, N.C, Nov. 21, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage...
ProKidney Reports Third Quarter Financial Results
ProKidney Reports Third Quarter Financial Results
WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics...
ProKidney appoints new CEO, updates Phase 3 plans for REACT therapy (NASDAQ:PROK)
ProKidney (PROK) has appointed a new CEO and updated its Phase 3 program to focus on advanced diabetic chronic kidney disease. Read more here.
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients ...
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
Total of 6 abstracts accepted for publication in Kidney Week 2023 program
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
Total of 6 abstracts accepted for publication in Kidney Week 2023 program...
Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?
PROK stock is in focus following a slew of sales from SPAC sponsor Chamath Palihapitiya. Here's what you need to know.
Prokidney says Palihapitiya Chamath sells ~486.9K shares (NASDAQ:PROK)
Prokidney's stock price gains momentum as shareholder Palihapitiya Chamath sells significant shares within a price range of $2.6-$3.8 per share.
Why Shares of ProKidney Were Dropping Thursday
Two factors led to the stock's slide on Thursday.
ProKidney is Now Oversold (PROK)
Chamath Palihapitiya discloses sale of 1.7M ProKidney shares (NASDAQ:PROK)
Chamath Palihapitiya, a 10% owner of ProKidney (PROK), sells 1.7 million shares for $9.3 million. He now owns 2,073,000 shares. Limited recent trading activity.